Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data

Journal of Medicinal Chemistry

Volumn 47, Issue 24, 2004, Pages 5953-5961

  Shuman, Cynthia F ^a   Vrang, Lotta ^b   Danielson, U Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

A 015; A 016; A 017; A 018; A 021; A 023; A 024; A 030; A 037; A 038; A 045; A 047; AMPRENAVIR; ATAZANAVIR; B 249; B 268; B 277; B 295; B 322; B 347; B 355; B 365; B 369; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; BIOSENSOR; CELL CULTURE; CLUSTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; STRUCTURE ACTIVITY RELATION; VIRUS PARTICLE;

BIOSENSING TECHNIQUES; CELLS, CULTURED; CLUSTER ANALYSIS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 8644247487     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0499110     Document Type: Article

References (25)

1. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
2. De Clercq, E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int. J. Biochem. Cell Biol. 2004, 36, 1800-1822.
3. Tummino, P. J.; Prasad, J. V.; Ferguson, D.; Nouhan, C.; Graham, N.; Domagala, J. M.; Ellsworth, E.; Gajda, C.; Hagen, S. E.; Lunney, E. A.; Para, K. S.; Tait, B. D.; Pavlovsky, A.; Erickson, J. W.; Gracheck, S.; McQuade, T. J.; Hupe, D. J. Discovery and optimization of nonpeptide HIV-1 protease inhibitors. Bioorg. Med. Chem. 1996, 4, 1401-1410.
4. De Lucca, G. V.; Liang, J.; De Lucca, I. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors. J. Med. Chem. 1999, 42, 135-152.
5. Alterman, M.; Andersson, H. O.; Garg, N.; Ahlsén, G.; Lövgren, S.; Classon, B.; Danielson, U. H.; Kvarnström, I.; Vrang, L.; Unge, T.; Samuelsson, B.; Hallberg, A. Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1́-modified HIV-1 protease inhibitors. J. Med. Chem. 1999, 42, 3835-3844.
6. Pyring, D.; Lindberg, J.; Rosenquist, A.; Zuccarello, G.; Kvarnstrom, I.; Zhang, H.; Vrang, L.; Unge, T.; Classon, B.; Hallberg, A.; Samuelsson, B. Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution. J. Med. Chem. 2001, 44, 3083-3091.
7. Hämäläinen, M. D.; Markgren, P.-O.; Schaal, W.; Karlén, A.; Classon, B.; Vrang, L.; Samuelsson, B.; Hallberg, A.; Danielson, U. H. Characterization of a set of HIV-1 protease inhibitors using binding kinetic data from a biosensor-based screen. J. Biomol. Screening 2000, 5, 353-359.
8. Gulnik, S. V.; Suvorov, L. I.; Liu, B.; Yu, B.; Anderson, B.; Mitsuya, H.; Erickson, J. W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995, 34, 9282-9287.
9. Wilson, S. I.; Phylip, L. H.; Mills, J. S.; Gulnik, S. V.; Erickson, J. W.; Dunn, B. M.; Kay, J. Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. Biochim. Biophys. Acta 1997, 1339, 113-125.
10. Pazhanisamy, S.; Stuver, C. M.; Cullinan, A. B.; Margolin, N.; Rao, B. G.; Livingston, D. J. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 1996, 271, 17979-17985.
11. Klabe, R. M.; Bacheler, L. T.; Ala, P. J.; Erickson-Viitanen, S.; Meek, J. L. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 1998, 37, 8735-8742.
12. Hurwitz, S. J.; Schinazi, R. F. Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antiviral Res. 2002, 56, 115-127.
13. Markgren, P.-O.; Lindgren, M. T.; Gertow, K.; Karlsson, R.; Hämäläinen, M.; Danielson, U. H. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Anal. Biochem. 2001, 291, 207-218.
14. Markgren, P.-O.; Schaal, W.; Hämäläinen, M.; Karlén, A.; Hallberg, A.; Samuelsson, B.; Danielson, U. H. Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J. Med. Chem. 2002, 45, 5430-5439.
15. Shuman, C. F.; Markgren, P.-O.; Hämäläinen, M.; Danielson, U. H. Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Res. 2003, 58, 235-242.
16. Shuman, C. F.; Hämäläinen, M.; Danielson, U. H. Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J. Mol. Recognit. 2004, 17, 106-119.
17. Ahlsén, G.; Hultén, J.; Shuman, C. F.; Poliakov, A.; Lindgren, M. T.; Alterman, M.; Samuelsson, B.; Hallberg, A.; Danielson, U. H. Resistance profiles of cyclic and linear inhibitors of HIV-1 protease. Antivir. Chem. Chemother. 2002, 13, 27-37.
18. Nillroth, U.; Vrang, L.; Markgren, P. O.; Hultén, J.; Hallberg, A.; Danielson, U. H. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogues. Antimicrob. Agents Chemother. 1997, 41, 2383-2388.
19. Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C. M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
20. Weislow, O. S.; Kiser, R.; Fine, L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble Formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
21. StatSoft I. STATISTICA (data analysis software system), version 6. www.statsoft.com, 2001.
22. Briggs, J. A.; Wilk, T.; Welker, R.; Kräusslich, H. G.; Fuller, S. D. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 2003, 22, 1707-1715.
23. Turner, B. G.; Summers, M. F. Structural biology of HIV. J. Mol. Biol. 1999, 285, 1-32.
24. Gossas, T.; Danielson, U. H. Kinetic analysis of the interaction between HIV-1 protease and inhibitors in different buffer environments. J. Mol. Recognit. 2003, 16, 203-212.
25. Szeltner, Z.; Polgár, L. Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration. J. Biol. Chem. 1996, 271, 5458-5463.